Archives of Psychiatry
Research, a new name for a steadfast focus on psychiatric research

Dear colleagues and readers, from its 55th volume in 2019, Alcoholism and Psychiatry Research, Journal on psychiatric research and addictions, will change its name to Archives of Psychiatry Research, An International Journal of Psychiatry and Related Sciences. This name change reflects continuous efforts by the editorial office to broaden the Journal’s scope of interest, as the previous one of addictology significantly encumbered the editorial process. This is especially the case in the recent years, especially after 2015, with an increasing inflow of new articles, not necessarily falling in the category of addiction and substance dependence. We are aware that this is a big change for the Journal, and to a somewhat lesser extent for our scientific community. However, due to a growing interest of authors willing to publish their research in Alcoholism and Psychiatry Research, and enthusiastic support by Naklada Slap, we feel that it is the right moment for such a shift of focus. That being said, it is our firm belief that we remain on the right course set by Vladimir Hudolin in 1965 when he founded Alcoholism, Journal on Alcoholism and Related Addictions. To support this statement we must stress the fact that this Journal has been continuously published for well over fifty years, without volumes becoming double editions. Furthermore, recently the Journal has successfully met the criteria for indexation in the Directory of Open Access Journals/DOAJ, as well as launched its first ever web page at http://apr.kbcsm.hr and set up its online manuscript submission system. The editorial board has also seen several changes, which also reflect the new course set by the Editorial Office in order to broaden the potential reader and author base and encompass a wider array of psychiatric topics. After all, it is a great pleasure and honour to continue in the footsteps of our predecessors (Vladimir Hudolin, Branko Lang, Vladko Thaller and Danijel Buljan), albeit that compels us to adhere to their high professional criteria.
Neatly coinciding with the change of journal’s name, with this issue we plan to introduce a new section of this journal. This section, titled *Back to the Future of Psychopharmacology* will focus on psychopharmaceutical modalities that have undergone the conceptualisation phase and are in one of the phases of molecule development. This includes an additional mechanism of action in an already established molecule or combinations of several existing psychopharmacological treatment modalities. In a broader sense we will address entirely new concepts in psychopharmacology, with emphasis on their potential clinical applicability. Lately we have been witnessing serious struggles in development of new molecules, with increased difficulty of meeting the criteria set by pre-clinical and clinical drug studies. Hence, not all molecules presented in this section will eventually take off as a clinically used psychopharmaceutical. Nevertheless, curiosity and the need to develop new treatment modalities with respect to their clinical efficiency and safety, entices us to explore psychopharmacological horizons while we await new therapeutic possibilities.

*Assistant Professor Vjekoslav Peitl, MD, PhD*

*Deputy Editor*